1
                                                                    Exhibit 23.1

                        Independent Accountant's Consent





The Board of Directors and Stockholders
Anthra Pharmaceuticals, Inc.:




We consent to the use of our report included herein and to the references to our
firm under the headings "Selected Consolidated Financial Data" and "Experts" in
the prospectus. Our report dated August 12, 1998 contains an explanatory
paragraph that states that the Company has suffered recurring losses from
operations, has a net capital deficiency and has insufficient working capital to
fund its current operating requirements, which raise substantial doubt about its
ability to continue as a going concern. The consolidated financial statements do
not include any adjustments that might result from the outcome that uncertainty.



Princeton, New Jersey
November 13, 1998